Seres Therapeutics, Inc.
serestherapeutics.comWhat Do They Do?
Develops oral live biotherapeutic drug candidates for patients with inflammatory and immune diseases and medically vulnerable patients at risk of infection.
10-K for FY2025, filed Mar 12, 2026We are a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through discovery and development…View ↗
SER-155, our most advanced LBP candidate, is an investigational, oral, live biotherapeutic designed to decolonize GI pathogens, improve GI…View ↗
Our current strategy prioritizes advancing our programs that target I&I indications. We have meaningfully advanced over the past decade our…View ↗
How Do They Make Money?
$789K
-
10-K for FY2025, filed Mar 12, 2026
$789K ↗
Do Revenues Turn Into Profits?
Yes. Its net income in FY2025 was larger than its revenue and turned 110 cents into free cash flow.
10-K for FY2025, filed Mar 12, 2026
−$94MView ↗
10-K for FY2025, filed Mar 12, 2026
$5.7MView ↗
10-K for FY2025, filed Mar 12, 2026
$865KView ↗
How Are They Changing?
Shrinking. Revenue fell 99% in 4 years, from $144.9M in FY2021 to $789K in FY2025, about 73% a year.
From a lead drug to an I&I pipeline
The older report prioritized a microbiome drug for recurrent C. difficile infection and potential commercialization; the latest prioritizes earlier-stage inflammatory and immune programs after the VOWST business was sold.
10-K for FY2022, filed Mar 7, 2023 10-K for FY2025, filed Mar 12, 2026
Loading...
